Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 30, 2022

Revenue from Contract with Customer [Abstract]

The following table reflects activity in the Company's sales reserve accounts:


	Rebates and Chargebacks (1)		Product Returns		Other Sales Deductions		Total
Balance as of December 27, 2019 (Predecessor)	$	295.8	$	28.4	$	13.2	$	337.4
Provisions	2,065.9		28.9		59.5		2,154.3
Provision for Medicaid lawsuit (2)	536.0		—		—		536.0
Payments or credits	(2,701.2)		(30.7)		(60.4)		(2,792.3)
Balance as of December 25, 2020 (Predecessor)	196.5		26.6		12.3		235.4
Provisions	2,087.1		23.7		55.2		2,166.0
Payments or credits	(2,041.8)		(28.8)		(58.0)		(2,128.6)
Balance as of December 31, 2021 (Predecessor)	241.8		21.5		9.5		272.8
Provisions	693.4		5.2		17.1		715.7
Payments or credits	(684.6)		(8.1)		(18.9)		(711.6)
Balance as of June 16, 2022 (Predecessor)	$	250.6	$	18.6	$	7.7	$	276.9


Balance as of June 17, 2022 (Successor)	$	250.6	$	18.6	$	7.7	$	276.9
Provisions	804.4		7.0		36.7		848.1
Payments or credits	(789.7)		(9.6)		(31.7)		(831.0)
Balance as of December 30, 2022 (Successor)	$	265.3	$	16.0	$	12.7	$	294.0

(1)Includes $89.3 million and $49.6 million of accrued Medicaid and $55.3 million and $30.4 million of accrued rebates as of December 30, 2022 and December 31, 2021, respectively, included within accrued and other current liabilities in the consolidated balance sheets.

(2)Excludes the $105.1 million that is reflected as a component of operating expenses as it represents a pre-acquisition contingency related to the portion of the liability that arose from sales of Acthar Gel prior to the Company's acquisition of Questcor in August 2014.

Disaggregation of Revenue

Product sales transferred to customers at a point in time and over time were as follows:


	Successor		Predecessor
	Period from June 17, 2022 through December 30, 2022		Period from January 1, 2022 through June 16, 2022		Year Ended December 31, 2021		Year Ended December 25, 2020
Product sales transferred at a point in time	83.0	%	80.8	%	79.4	%	78.9	%
Product sales transferred over time	17.0		19.2		20.6		21.1

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction

Transaction price allocated to the remaining performance obligations

The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of December 30, 2022 (Successor):


Fiscal 2023	$	115.4
Fiscal 2024	23.5
Thereafter	2.7

Disaggregation of Revenue - Royalty

The associated royalty revenue recognized was as follows:


	Successor		Predecessor
	Period from June 17, 2022 through December 30, 2022		Period from January 1, 2022 through June 16, 2022		Year Ended December 31, 2021		Year Ended December 25, 2020
Royalty revenue	$	36.2	$	34.9	$	102.4	$	70.3